Alan Coates
#105,625
Most Influential Person Now
Australian clinical oncologist
Alan Coates's AcademicInfluence.com Rankings
Alan Coatesmedical Degrees
Medical
#1727
World Rank
#2097
Historical Rank
Oncology
#111
World Rank
#115
Historical Rank
Alan Coatesphilosophy Degrees
Philosophy
#7451
World Rank
#10670
Historical Rank
Logic
#4499
World Rank
#5804
Historical Rank
Download Badge
Medical Philosophy
Alan Coates's Degrees
- Bachelors Medicine University of Melbourne
- PhD Oncology University of Melbourne
Why Is Alan Coates Influential?
(Suggest an Edit or Addition)According to Wikipedia, Alan Stuart Coates is an Australian professor of clinical oncology, medical researcher and administrator. He was the inaugural CEO of the Cancer Council Australia , former president of the Clinical Oncological Society of Australia , and co-chair of the St. Gallen International Breast Cancer Conference. He was also the first non-American to be elected to the board of directors of the American Society of Clinical Oncology.
Alan Coates's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
- Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011) (3214)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
- A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. (2004) (1787)
- A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. (2005) (1554)
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015) (1499)
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 (2009) (1391)
- Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005) (1184)
- Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. (2013) (989)
- Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. (2007) (937)
- Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. (2007) (890)
- Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. (2003) (727)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
- Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. (2014) (612)
- Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. (2001) (535)
- Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. (1987) (523)
- Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. (2010) (518)
- Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. (2009) (486)
- Adjuvant ovarian suppression in premenopausal breast cancer. (2015) (467)
- On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. (1996) (412)
- Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. (2007) (388)
- Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. (2008) (367)
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. (2011) (358)
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer (2018) (348)
- CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. (2012) (332)
- Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. (2016) (329)
- Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. (2008) (329)
- Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. (1992) (322)
- Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. (1989) (311)
- Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. (1997) (305)
- Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. (2000) (296)
- Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. (1998) (278)
- Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. (2018) (274)
- Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. (2013) (268)
- Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. (2003) (256)
- Experience with 998 cutaneous melanomas of the head and neck over 30 years. (1991) (235)
- Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. (2006) (234)
- Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. (2008) (233)
- Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. (1998) (226)
- Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. (2000) (220)
- Missing quality of life data in cancer clinical trials: serious problems and challenges. (1998) (210)
- Desmoplastic and desmoplastic neurotropic melanoma (1998) (209)
- Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. (2001) (207)
- Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. (2008) (206)
- Adjuvant therapy for very young women with breast cancer: need for tailored treatments. (2001) (198)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. (2008) (194)
- Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers (2010) (189)
- Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. (2006) (178)
- Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer (1996) (175)
- Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. (2002) (170)
- Ki‐67 expression in breast carcinoma (2003) (166)
- Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. (2014) (165)
- Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. (2016) (157)
- Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. (2000) (151)
- Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? (2001) (151)
- Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. (2008) (150)
- Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. (1993) (148)
- Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. (2002) (148)
- Psychosocial predictors of survival in metastatic melanoma. (1999) (148)
- Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. (2010) (137)
- Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. (2008) (136)
- Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. (2011) (136)
- Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. (2016) (134)
- Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. (2015) (127)
- Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. (2006) (127)
- Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. (1993) (127)
- Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. (2007) (127)
- Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis (2001) (127)
- Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index (2005) (125)
- Identifying breast cancer patients at high risk for bone metastases. (2000) (122)
- Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. (2015) (122)
- Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? (2005) (118)
- Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. (2011) (113)
- Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. (2012) (108)
- Cerebral metastases from malignant melanoma. (1992) (104)
- First--select the target: better choice of adjuvant treatments for breast cancer patients. (2006) (103)
- Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. (2008) (103)
- A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. (1995) (101)
- The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer (1993) (98)
- Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. (2017) (92)
- Clinical relevance of single item quality of life indicators in cancer clinical trials (2001) (92)
- Radical, modified, and selective neck dissection for cutaneous malignant melanoma (1995) (91)
- Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. (2004) (91)
- Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. (2016) (90)
- Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. (1996) (89)
- Breast cancer: delays, dilemmas, and delusions (1999) (88)
- Psychosocial predictors of survival: metastatic breast cancer. (2000) (88)
- Effect of systemic adjuvant treatment on first sites of breast cancer relapse (1994) (86)
- Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. (2001) (85)
- Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. (2005) (83)
- Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. (2017) (83)
- The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials (1993) (82)
- On the receiving end. IV: Validation of quality of life indicators. (1991) (82)
- Psychosocial predictors of outcome: time to relapse and survival in patients with early stage melanoma (2000) (81)
- Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. (2018) (81)
- Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. (2018) (79)
- Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. (2013) (77)
- Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. (2010) (75)
- The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. (2007) (73)
- Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means? (1991) (73)
- Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach (1998) (73)
- Quality of life scores predict outcome in metastatic but not in early breast cancer (2001) (73)
- Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group. (1998) (73)
- Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. (1998) (71)
- Screening decreases prostate cancer death: first analysis of the1988 Quebec Prospective Randomized Controlled Trial (2004) (70)
- Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study Group. (1992) (68)
- Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. (2006) (64)
- Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT (2019) (64)
- Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF (2002) (64)
- Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG). (1998) (63)
- Is adjuvant chemotherapy useful for women with luminal a breast cancer? (2012) (62)
- Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. (2010) (61)
- Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198 (2007) (60)
- Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. (1985) (59)
- Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial (2011) (59)
- Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. (2016) (59)
- Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93 (2008) (59)
- Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991. (1995) (59)
- Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. (2003) (58)
- Elective lymph node dissection. (1995) (58)
- Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. (2007) (58)
- Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer (1998) (58)
- Patterns over time in quality of life, coping and psychological adjustment in late stage melanoma patients: An application of multilevel models (2000) (57)
- Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? (2008) (56)
- Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS‐II DCIS) (2008) (55)
- Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer (2006) (54)
- Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT (2017) (54)
- Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX (2012) (53)
- Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. (2012) (51)
- Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century (2009) (51)
- Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. (2019) (51)
- Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. (2013) (49)
- Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile? (2005) (49)
- Decreased immunoreactivity for p27 protein in patients with early‐stage breast carcinoma is correlated with HER‐2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status (2003) (48)
- International Breast Cancer Study Group trials. (1998) (48)
- Coping with metastatic melanoma: the last year of life (2000) (47)
- Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer (2007) (46)
- Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series (2009) (45)
- Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. (1997) (45)
- Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11– (2001) (44)
- Immunopathological comparisons between experimental autoimmune encephalomyelitis and multiple sclerosis. (1973) (42)
- Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer (2010) (42)
- Cellular-immune response to myelin protein: absence in multiple sclerosis and presence in cerebrovascular accidents. (1974) (41)
- Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (1999) (41)
- Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy (2010) (40)
- Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG) (1995) (40)
- An evidence-based specialist breast nurse role in practice: a multicentre implementation study. (2003) (40)
- Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials (2015) (38)
- BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. (2009) (38)
- Phase-II Study of Recombinant α2-Interferon in Advanced Malignant Melanoma (1986) (38)
- Trends in survival and excess risk of death after diagnosis of cancerin 1980–1996 in New South Wales, Australia (2006) (37)
- Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy (2001) (36)
- Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG). (1998) (36)
- Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. (2003) (35)
- Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer (1993) (35)
- Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93 (2009) (35)
- Immunological effects of recombinant interferon alfa‐2a in patients with disseminated melanoma (1986) (34)
- Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials. (1998) (33)
- Adjuvant ovarian function suppression and cognitive function in women with breast cancer (2016) (33)
- Chemotherapy for Advanced Breast Cancer – How Long Should it Continue? (2003) (32)
- Cancer prevention: a global perspective. (2005) (31)
- Chemotherapy of advanced ovarian adenocarcinoma: a randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin. (1986) (30)
- Long term response to chemotherapy in patients with visceral metastatic melanoma. (1994) (30)
- Quality of life and supportive care (1997) (30)
- Adjuvant therapy for breast cancer: understanding the overview. International Breast Cancer Study Group. (1993) (30)
- Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma (1987) (30)
- Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. (2009) (29)
- Chemotherapy for metastatic breast cancer--when is enough enough? (1997) (28)
- Systemic adjuvant treatment for premenopausal node-negative breast cancer. The International Breast Cancer Study Group. (2000) (27)
- Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. (1997) (27)
- Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. (1997) (27)
- CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial (2015) (26)
- Radiotherapy and chemotherapy in high-risk breast cancer. (1998) (25)
- Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer (2004) (25)
- Molecular biomarkers to individualise treatment: assessing the evidence (2009) (25)
- A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. (2008) (25)
- Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. (2005) (25)
- Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. (2008) (24)
- Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group. (1994) (24)
- Redressing the balance--the ethics of not entering an eligible patient on a randomised clinical trial. (1992) (24)
- Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial (2017) (23)
- Special article: Redressing the balance - The ethics of not entering an eligible patient on a randomised clinical trial Point of view (1992) (23)
- Keeping faith with trial volunteers (2007) (23)
- Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII. (2016) (23)
- Adjuvant!© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer (2010) (23)
- Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. (2014) (22)
- Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer (2012) (20)
- Tailoring adjuvant treatments for the individual breast cancer patient. (2003) (20)
- Subsets within the chemotherapy overview (1998) (20)
- Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial (2016) (20)
- Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. (1998) (19)
- Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT. (2018) (19)
- Overhauling the breast cancer overview: are subsets subversive? (2002) (18)
- Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with node-positive (N+), early stage breast cancer: first results of International Breast Cancer Study Group Trial 13–93 (2004) (18)
- Prognostic implications of quality of life. (1993) (18)
- Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data. (1998) (18)
- Long-Term Follow-Up of the Intergroup Exemestane Study. (2017) (18)
- Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy (2020) (18)
- Refining the measurement of psychological adjustment in cancer (1997) (18)
- p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. (2007) (18)
- Present and future projects of the international breast cancer study group (1994) (17)
- Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. (2016) (17)
- Abstract P5-13-01: Patterns of Breast Cancer Relapse According to Breast Cancer Subtypes in Lymph Node-Negative Breast Cancer — Results from International Breast Cancer Study Group Trials VIII and IX (2010) (17)
- On the receiving end. VI. Which dimensions of quality-of-life scores carry prognostic information? (1996) (17)
- Leucocytoclastic vasculitis and skin necrosis following subcutaneous heparin calcium. (1982) (17)
- The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause (2011) (16)
- Patterns of metastases in familial and non-familial melanoma (2003) (16)
- Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (2013) (16)
- Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. (1997) (16)
- ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer (2015) (16)
- Supplementary Material 1 (2010) (15)
- Abstract S2-05: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer: A randomized, phase 2 study (2017) (15)
- Common bile duct obstruction due to intraluminal metastatic melanoma. (1993) (15)
- Disease Related Outcome with Long Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study (IES). (2009) (14)
- Taxanes as adjuvant for breast cancer (2000) (14)
- Abstract S1-1: Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. (2012) (14)
- Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron. (1992) (13)
- Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. (1993) (13)
- Surgical resection of pulmonary metastatic melanoma: A review of 83 thoracotomies (1996) (13)
- Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group (2007) (13)
- Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question? (1998) (13)
- Is chemotherapy for non-small cell lung cancer worthwhile? (1993) (13)
- Prognostic value of performance status and quality-of-life scores during chemotherapy for advanced breast cancer. The Australian New Zealand Breast Cancer Trials Group. (1993) (12)
- Systemic chemotherapy for malignant melanoma (1992) (12)
- Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. (2021) (11)
- Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: The open questions (2003) (11)
- Historical cross-trial comparisons for competing treatments in advanced breast cancer--an empirical analysis of bias. (2010) (11)
- A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer (2011) (11)
- Duration of chemotherapy for metastatic breast cancer (2004) (10)
- Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. (2007) (10)
- Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma. (1986) (10)
- Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial (2015) (10)
- What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer? (2005) (9)
- Quality of life studies of the Australian New Zealand Breast Cancer Trials Group: approaches to missing data. (1998) (9)
- Quality of life assessment in the International Breast Cancer Study Group: past, present, and future. (1998) (9)
- Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC). (2015) (9)
- When do patient reported quality of life indicators become prognostic in breast cancer? (2018) (9)
- Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. (2019) (9)
- Features that predict responsiveness to chemotherapy and endocrine therapies (2001) (9)
- Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma. (1991) (8)
- Single‐agent versus combination antiemetic treatments in patients receiving cytotoxic chemotherapy (1982) (8)
- Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences (2014) (8)
- Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence (2019) (8)
- Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1–98 (2007) (8)
- Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma. (1986) (8)
- Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma. (2013) (8)
- Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. (2009) (7)
- Subsets within the chemotherapy overview. International Breast Cancer Study Group. (1998) (7)
- Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. (2015) (7)
- Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po (2015) (7)
- Prediction of cancer outcome with microarrays (2005) (7)
- Meta-analysis: the fashion of summing-up evidence. Part II: Interpretations and uses. (1992) (7)
- Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam). (2014) (7)
- SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC). (2017) (7)
- Adjusting for Selective Crossover in Analyses of Letrozole (Let) Versus Tamoxifen (Tam) in the BIG 1-98 Trial. (2009) (7)
- Management of early breast cancer: an Australian consensus report. Clinical Oncological Society of Australia, the Australian-New Zealand Breast Cancer Trials Group, the Medical Oncology Group of Australia and the Breast Section, Royal Australasian College of Surgeons. (1995) (6)
- Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with node-positive (N+), early stage breast cancer: first results of International Breast Cancer Study Group Trial 13-93. (2004) (6)
- Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. (2009) (6)
- Acute leukaemia following chemotherapy including etoposide for testicular carcinoma. (1993) (6)
- Desmoplastic and desmoplastic neurotropic melanoma: 119 (1997) (6)
- How to improve timing and duration of adjuvant chemotherapy (2001) (5)
- Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00 (2018) (5)
- Thermal neutron capture therapy: the Japanese-Australian clinical trial for malignant melanoma. (1989) (5)
- Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron. (1994) (5)
- Eosinophilic leukaemoid reaction and interleukin‐5 in metastatic melanoma (1998) (5)
- Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case. (1977) (5)
- Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. (1986) (5)
- Aromatase inhibitors (AI) for elderly patients: Efficacy, compliance and safety according to patient age in the BIG 1–98 trial (2007) (5)
- Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (2019) (5)
- Immunologic function during adjuvant BCG immunotherapy for malignant melanoma: Induction of anergy (1979) (5)
- Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Women With Early Breast Cancer: Results From the BIG 1-98 Collaborative Groups (2007) (4)
- Meta AMSA (m‐AMSA) in Patients with Advanced Ovarian Carcinoma (1982) (4)
- p 27 and Skp 2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer (2009) (4)
- Carcinoembryonic antigen in renal allograft recipients and immunosuppressed renal patients. (1977) (4)
- A review of 567 cases of brain metastases from malignant melanoma: 141 (1993) (4)
- Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial (2020) (4)
- Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma (2004) (4)
- Psychosocial predictors of outcome IV: patients with early-stage breast cancer (2001) (3)
- Tamoxifen (TAM) for the prevention of breast cancer: Importance of specific aspects of health-related quality of life (HRQL) to global health status in the ANZ BCTG substudy of IBIS-1 (ANZ 92P1) (2008) (3)
- PG 0.1 Evolution of the St.Gallen Consensus process for the optimal treatment of women with breast cancer (2015) (3)
- 5016 POSTER DISCUSSION BIG 1-98 Update: Evaluating Letrozole and Tamoxifen Alone and in Sequence at 8 Years Median Follow-up for Postmenopausal Women With Steroid Hormone Receptor-Positive Breast Cancer (2011) (3)
- Preferences for adjuvant chemotherapy (ACT) in early breast cancer: The benefits needed to make extended treatment with docetaxel, doxorubicin, and CMF worthwhile (2007) (3)
- Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al (2017) (3)
- Adjuvant treatment for breast cancer: the overview. (1992) (3)
- Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311 (2019) (3)
- Adjuvant therapy for breast cancer (1992) (3)
- Abstract P4-22-02: Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer (2017) (3)
- Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials (2022) (2)
- Metastatic melanoma presenting at diagnosis as a testicular mass. (1992) (2)
- Developing a core clinical data set for cancer (2003) (2)
- Ethics of randomized clinical trials. (1998) (2)
- The quality of quality-of-life measurements. (1995) (2)
- Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean). (2004) (2)
- Abstract P1-12-06: Co-SOFT: The cognitive function substudy of the suppression of ovarian function trial (SOFT) (2015) (2)
- New treatments for breast cancer: breakthroughs for patient care or just steps in the right direction? (1998) (2)
- Adjuvant ovarian suppression in premenopausal breast cancer | NOVA. The University of Newcastle's Digital Repository (2015) (2)
- 15 Vaccinia melanoma cell lysates (VMCL) in immunotherapy of stage lib and III melanoma (1999) (2)
- Breast cancer consensus (1994) (2)
- Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial (2020) (1)
- Clinical trials in breast cancer in Australia and New Zealand (1990) (1)
- Effect of Pregnancy on Overall Survival After the Diagnosis of Early-Stage Breast Cancer (2001) (1)
- Most common cancers: Breast cancer (2013) (1)
- The adjuvant treatment of elderly women with breast cancer (2004) (1)
- Results of first line endocrine therapy for advanced breast cancer in premenopausal women with skeletal metastases only (1993) (1)
- Patients’ Preferences: What Makes Treatments Worthwhile? (2006) (1)
- ETHICS OF RANDOMIZED CLINICAL TRIALS. AUTHOR'S REPLY (1998) (1)
- Abstract GS5-02: Axillary dissection vs. no axillary dissection in patients with cT1-T2cN0M0 breast cancer and only micrometastases in the sentinel node(s): Ten-year results of the IBCSG 23-01 trial (2018) (1)
- The survival of patients with malignant melanoma receiving BCG with or without chemotherapy. (1979) (1)
- Abstract PD1-03: Cholesterol, cholesterol lowering medication use, and breast cancer outcomes in the BIG 1-98 study (2016) (1)
- Plasma carcinoembryonic antigen in an Australian hospital population. (1976) (1)
- The future of breast cancer research and practice in Asia, Latin America, and the Middle East/North Africa: a qualitative horizon scanning analysis. (2009) (1)
- Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. (2010) (1)
- Abstract OT3-02-03: Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer (2017) (1)
- What troubles women starting chemotherapy (CT) for advanced breast cancer (ABC) in a randomized trial? (2004) (1)
- Treatment of advanced squamous‐cell carcinoma of the head and neck with a combination of cisplatin, vinblastine, and bleomycin (1984) (1)
- P107 Anemia during adjuvant chemotherapy for early breast cancer: incidence and risk factors – Results from the International Breast Cancer Study Group (IBCSG) (2007) (1)
- Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT (2022) (1)
- Hormonal treatment duration in elderly patients: an open question. (2004) (1)
- Reply to: prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer. (2014) (1)
- Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). (2004) (1)
- Quality-of-life considerations in the adjuvant setting: critical review. (1993) (1)
- Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial (2016) (1)
- Meet ing Highl ights : Updated Internat ional Expert Consensus on the Primary Therapy of Early Breast Cancer (2003) (1)
- Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX (2012) (1)
- Duration of adjuvant chemotherapy for breast cancer: A joint analysis of two randomized trials investigating 3 versus 6 courses of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) (2002) (1)
- Prognostic value of quality of life (QL) scores in a clinical trial of dacarbazine (DTIC) with or without interferon‐alpha2a (IFN) in patients with metastatic malignant melanoma (MMM): 151 (1993) (1)
- 33 Interim analysis of a randomised trial of immunotherapy with vaccinia melanoma cell lysates (1997) (1)
- Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials (2022) (0)
- The timing of ovarian function suppression (OFS) with chemotherapy in premenopausal women with endocrine-responsive HER2-negative early breast cancer: a secondary analysis of TEXT and SOFT (2017) (0)
- Quality of Life Measures as Endpoints and Prognostic Factors in Advanced Breast Cancer (1994) (0)
- Meeting H ighlights: U pdated I nternational E xpert C onsensus on t he P rimary T herapy o f E arly B reast C ancer (2003) (0)
- International consensus on treatment of early breast cancer: radiotherapy issues A response to 'International expert consensus on radiotherapy of early breast cancer'. (2007) (0)
- Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (2020) (0)
- Meet ing Highl ights : Internat ional Consensus Panel on the Treatment of Pr imary Breast Cancer (2001) (0)
- Reply to: Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer. (2014) (0)
- How to cope with melanoma: does patient behaviour influence outcome? (1997) (0)
- 353 Safety of letrozole and tamoxifen monotherapy: updated BIG 1-98 (2010) (0)
- The above letter was referred to the authors, who respond as follows: (1992) (0)
- Abstract P2-09-05: 12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer (2017) (0)
- Early S tart o f A djuvant C hemotherapy M ay I mprove Treatment O utcome f or P remenopausal B reast C ancer Patients W ith T umors n ot E xpressing E strogen R eceptors (2000) (0)
- Preliminary Summary of the Consensus Discussion (2013) (0)
- Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC) (2004) (0)
- Influence of Cellular DMA Content on Survival in Advanced Ovarian Cancer (2006) (0)
- False negatives in oestrogen-receptor assay (2000) (0)
- Adjuvant I mmunotherapy o f P atients W ith H igh-Risk Melanoma U sing V accinia V iral L ysates o f M elanoma: Results o f a R andomized T rial (2002) (0)
- S38 Quality of life measurements in the IBCSG: Past, present and future (1998) (0)
- Abstract P1-12-01: CYP19A1 and ESR1 polymorphisms and selected early-onset side effects during combined endocrine therapy in the IBCSG TEXT trial for premenopausal women with hormone receptor-positive (HR+) early breast cancer (2015) (0)
- Reporting Results from Adjuvant Therapy Trials with Special Emphasis on Quality-of-Life Findings (1992) (0)
- Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (2019) (0)
- Referees, 1985 (1986) (0)
- Perioperative chemotherapy in patients with node-negative postmenopausal breast cancer. (2002) (0)
- Evaluation of Adjuvant! Online to predict the effect of optimal endocrine therapy (ovarian function suppression plus tamoxifen) for premenopausal breast cancer patients with estrogen-receptor-positive breast cancer. (2009) (0)
- Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. (2023) (0)
- Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence (2019) (0)
- Abstract P5-09-01: Improving Informed Consent: Evaluating the First Decision Aid in a Clinical Trial Setting (IBIS-II Breast Cancer Prevention Trial) (2010) (0)
- Abstract P4-18-03: IBCSG BIG 1-98 study: The long-term follow-up experience: (2015) (0)
- Meeting H ighlights: I nternational C onsensus P anel o n t he Treatment o f P rimary B reast C ancer (2001) (0)
- Impact of Adjuvant Chemotherapy Followed By Goserelin Compared With Either Modality Alone on Amenorrhea, Hot Flashes, and Quality of Life in Premenopausal Patients With Lymph Node-Negative Breast Cancer: Results on the Effect of Age From the International (2006) (0)
- Abstract OT1-01-03: The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer (2019) (0)
- Abstract P1-10-06: A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for primary endocrine responsive breast cancer (TREND; IBCSG 41-13) (2018) (0)
- Identifying B reast C ancer P atients a t H igh R isk f or Bone M etastases (2000) (0)
- The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer (2019) (0)
- Treatment of advanced squamous cell carcinoma of head and neck with cisplatin and continuous 96 hour infusion of 5-fluorouracil. (1989) (0)
- Effect o f P regnancy o n O verall S urvival A fter t he Diagnosis o f E arly-Stage B reast C ancer (2001) (0)
- The impact of quality of life (QL) scores on survival in patients with metastatic breast cancer (MBC) (1998) (0)
- Influence o f E ndocrine-Relate d F actors o n R esponse t o Perioperative C hemotherapy f or P atients W ith N ode- Negative B reast C ancer (2001) (0)
- How much improvement in survival do early breast cancer patients require to consider endocrine therapy worthwhile (2001) (0)
- Abstract P6-08-04: Prognostic significance of quality-of-life scores in early stage and relapsed breast cancer: Results from seven randomized trials of the International breast cancer study group (2013) (0)
- The St Gallen point of view: How do yoy select treatment for “average/high risk” node-negative patients? (2001) (0)
- Role of elective lymph node dissection in primary malignant melanoma 1.5 mm or thicker of the trunk and limbs without clinical node metastases: 392 (1993) (0)
- Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (2020) (0)
- Adjuvant Chemotherapy for Locoregional Recurrent Breast Cancer (2011) (0)
- Effect of Pregnancy on Overal l Surv iva l Af ter the Diagnosis of Ear ly-Stage Breast Cancer (2001) (0)
- 301PPREDICTORS OF HYPERTENSION IN IBCSG 18-98 / BIG 1-98: ADJUVANT THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, EARLY BREAST CANCER. (2014) (0)
- Subjective cognitive complaints one year after ceasing adjuvant endocrine therapy for early-stage breast cancer: Findings from the Breast International Group (BIG) 1-98 trial. (2012) (0)
- LIVER BIOPSY REQUEST FORM: A DIAGNOSTIC AID (1973) (0)
- Predicting Survival Time in Women Starting First Line Chemotherapy for Advanced Breast Cancer. (2009) (0)
- Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses. (2019) (0)
- Outcomes of first-line chemotherapy for advanced breast cancer in women with good versus poor quality of life at baseline. (2016) (0)
- The Legacy of Professor Aron Goldhirsch. (2020) (0)
- Randomized P hase I II S tudy o f T emozolomide V ersus Dacarbazine i n t he T reatment o f P atients W ith A dvanced Metastatic M alignant M elanoma (2000) (0)
- Intrinsic subtype and its clinical significance in early node-negative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy. (2012) (0)
- Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer? (2009) (0)
- Chemotherapy For Metastatic Breast When is Enough Enough? Cancer - (1997) (0)
This paper list is powered by the following services:
Other Resources About Alan Coates
What Schools Are Affiliated With Alan Coates?
Alan Coates is affiliated with the following schools:
